All Stories

  1. Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure

    Article • Pharmaceutics, December 2019, MDPI AG

    Christopher Porter

  2. Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats

    Article • Journal of Controlled Release, December 2019, Elsevier

    Christopher Porter

  3. Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties

    Article • Molecular Pharmaceutics, November 2019, American Chemical Society (ACS)

    Christopher Porter

  4. A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats

    Article • European Journal of Pharmaceutics and Biopharmaceutics, April 2019, Elsevier

    Christopher Porter

  5. Pointing in the Right Direction: Controlling the Orientation of Proteins on Nanoparticles Improves Targeting Efficiency

    Article • Nano Letters, February 2019, American Chemical Society (ACS)

    Christopher Porter

  6. Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation

    Article • Journal of Controlled Release, February 2019, Elsevier

    Christopher Porter

  7. A Nonionic Polyethylene Oxide (PEO) Surfactant Model: Experimental and Molecular Dynamics Studies of Kolliphor EL

    Article • Journal of Pharmaceutical Sciences, January 2019, Elsevier

    Christopher Porter

  8. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations

    Article • Molecular Pharmaceutics, October 2018, American Chemical Society (ACS)

    Christopher Porter

  9. Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery

    Article • ACS Applied Materials & Interfaces, September 2018, American Chemical Society (ACS)

    Christopher Porter

  10. Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistribution

    Article • Biomaterials, September 2018, Elsevier

    Christopher Porter

  11. Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats

    Article • Journal of Pharmaceutical Sciences, September 2018, Elsevier

    Christopher Porter

  12. Minimum information reporting in bio–nano experimental literature

    Article • Nature Nanotechnology, September 2018, Springer Science + Business Media

    Christopher Porter

  13. Impact of Drug Physicochemical Properties on Lipolysis-Triggered Drug Supersaturation and Precipitation from Lipid-Based Formulations

    Article • Molecular Pharmaceutics, August 2018, American Chemical Society (ACS)

    Christopher Porter

  14. Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker

    Article • Molecular Pharmaceutics, August 2018, American Chemical Society (ACS)

    Christopher Porter

  15. Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels

    Article • Journal of Neurochemistry, July 2018, Wiley

    Professor Philip John Marriott, Christopher Porter

  16. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation

    Article • Molecular Pharmaceutics, May 2018, American Chemical Society (ACS)

    Christopher Porter

  17. Fatty Acid–Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells

    Article • Journal of Pharmaceutical Sciences, April 2018, Elsevier

    Professor Martin J Scanlon, Christopher Porter

  18. Lipids in the Stomach – Implications for the Evaluation of Food Effects on Oral Drug Absorption

    Article • Pharmaceutical Research, February 2018, Springer Science + Business Media

    Christopher Porter

  19. Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations

    Article • Journal of Pharmaceutical Sciences, January 2018, Elsevier

    Christopher Porter

  20. Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid diets

    Article • Journal of Neurochemistry, December 2017, Wiley

    Professor Philip John Marriott, Dr Kwok Ho Christopher Choy, Christopher Porter

  21. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623

    Article • Molecular Pharmaceutics, November 2017, American Chemical Society (ACS)

    Christopher Porter

  22. Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site

    Article • Nanomedicine Nanotechnology Biology and Medicine, November 2017, Elsevier

    Christopher Porter

  23. Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission

    Article • Proceedings of the National Academy of Sciences, October 2017, Proceedings of the National Academy of Sciences

    Christopher Porter

  24. Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies

    Article • Molecular Pharmaceutics, October 2017, American Chemical Society (ACS)

    Christopher Porter

  25. Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids

    Article • Molecular Pharmaceutics, October 2017, American Chemical Society (ACS)

    Christopher Porter

  26. Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers

    Article • European Journal of Pharmaceutics and Biopharmaceutics, October 2017, Elsevier

    Christopher Porter

  27. Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution

    Article • ACS Applied Materials & Interfaces, September 2017, American Chemical Society (ACS)

    Christopher Porter

  28. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration

    Article • Biomacromolecules, August 2017, American Chemical Society (ACS)

    Christopher Porter

  29. Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy

    Article • Nature Communications, July 2017, Nature

    Christopher Porter

  30. Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief

    Article • Science Translational Medicine, May 2017, American Association for the Advancement of Science

    Christopher Porter, Professor Martin J Scanlon

  31. Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids

    Article • Molecular Pharmaceutics, February 2017, American Chemical Society (ACS)

    Christopher Porter

  32. Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion

    Article • Molecular Pharmaceutics, February 2017, American Chemical Society (ACS)

    Christopher Porter

  33. Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods

    Article • Molecular Pharmaceutics, January 2017, American Chemical Society (ACS)

    Christopher Porter

  34. Fatty Acid-Binding Protein 5 at the Blood–Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function

    Article • Journal of Neuroscience, November 2016, Society for Neuroscience

    Christopher Porter, Professor Martin J Scanlon, Dr Kwok Ho Christopher Choy

  35. Frontispiece: Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability

    Article • Angewandte Chemie International Edition, October 2016, Wiley

    Christopher Porter

  36. Frontispiz: Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability

    Article • Angewandte Chemie, October 2016, Wiley

    Christopher Porter

  37. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability

    Article • Angewandte Chemie International Edition, August 2016, Wiley

    Christopher Porter

  38. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability

    Article • Angewandte Chemie, August 2016, Wiley

    Christopher Porter

  39. Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation

    Article • Molecular Pharmaceutics, June 2016, American Chemical Society (ACS)

    Christopher Porter

  40. 50years of oral lipid-based formulations: Provenance, progress and future perspectives

    Article • Advanced Drug Delivery Reviews, June 2016, Elsevier

    Christopher Porter

  41. Computational prediction of formulation strategies for beyond-rule-of-5 compounds

    Article • Advanced Drug Delivery Reviews, June 2016, Elsevier

    Christopher Porter

  42. Understanding the Challenge of Beyond-Rule-of-5 Compounds

    Article • Advanced Drug Delivery Reviews, June 2016, Elsevier

    Christopher Porter

  43. Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab′ Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity

    Article • Molecular Pharmaceutics, April 2016, American Chemical Society (ACS)

    Christopher Porter

  44. Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug

    Article • Journal of Pharmaceutical Sciences, February 2016, Elsevier

    Christopher Porter

  45. Tools for Early Prediction of Drug Loading in Lipid-Based Formulations

    Article • Molecular Pharmaceutics, January 2016, American Chemical Society (ACS)

    Christopher Porter

  46. Passive tumour targeting and extravasation of cylindrical polymer brushes in mouse xenografts

    Article • Chemical Communications, January 2016, Royal Society of Chemistry

    Christopher Porter

  47. The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats

    Article • Journal of Pharmaceutical Sciences, January 2016, Elsevier

    Christopher Porter

  48. A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations

    Article • Pharmaceutical Research, December 2015, Springer Science + Business Media

    Christopher Porter

  49. Fatty Acid-Binding Protein 5 Facilitates the Blood–Brain Barrier Transport of Docosahexaenoic Acid

    Article • Molecular Pharmaceutics, December 2015, American Chemical Society (ACS)

    Christopher Porter, Professor Martin J Scanlon

  50. Pluronic-Functionalized Silica–Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases

    Article • Molecular Pharmaceutics, December 2015, American Chemical Society (ACS)

    Christopher Porter

  51. Molecular weight (hydrodynamic volume) dictates the systemic pharmacokinetics and tumour disposition of PolyPEG star polymers

    Article • Nanomedicine Nanotechnology Biology and Medicine, November 2015, Elsevier

    Christopher Porter

  52. A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep

    Article • Pharmaceutical Research, October 2015, Springer Science + Business Media

    Christopher Porter

  53. From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity

    Article • Nature Reviews Drug Discovery, October 2015, Nature

    Christopher Porter

  54. Fatty Acid Binding Proteins Expressed at the Human Blood–Brain Barrier Bind Drugs in an Isoform-Specific Manner

    Article • Pharmaceutical Research, August 2015, Springer Science + Business Media

    Christopher Porter, Professor Martin J Scanlon

  55. Transformation of Poorly Water-Soluble Drugs into Lipophilic Ionic Liquids Enhances Oral Drug Exposure from Lipid Based Formulations

    Article • Molecular Pharmaceutics, May 2015, American Chemical Society (ACS)

    Christopher Porter

  56. Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor α in a Ligand-selective Manner

    Article • Journal of Biological Chemistry, April 2015, American Society for Biochemistry & Molecular Biology (ASBMB)

    Christopher Porter, Professor Martin J Scanlon

  57. Optimal PEGylation can Improve the Exposure of Interferon in the Lungs Following Pulmonary Administration

    Article • Journal of Pharmaceutical Sciences, April 2015, Elsevier

    Christopher Porter

  58. The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport

    Article • Journal of Visualized Experiments, March 2015, MyJove Corporation

    Christopher Porter

  59. Size and Rigidity of Cylindrical Polymer Brushes Dictate Long Circulating PropertiesIn Vivo

    Article • ACS Nano, February 2015, American Chemical Society (ACS)

    Christopher Porter

  60. PEGylation Does Not Significantly Change the Initial Intravenous or Subcutaneous Pharmacokinetics or Lymphatic Exposure of Trastuzumab in Rats but Increases Plasma Clearance after Subcutaneous Administration

    Article • Molecular Pharmaceutics, February 2015, American Chemical Society (ACS)

    Christopher Porter

  61. Methotrexate-Conjugated PEGylated Dendrimers Show Differential Patterns of Deposition and Activity in Tumor-Burdened Lymph Nodes after Intravenous and Subcutaneous Administration in Rats

    Article • Molecular Pharmaceutics, February 2015, American Chemical Society (ACS)

    Christopher Porter

  62. Profiling the Role of Deacylation-Reacylation in the Lymphatic Transport of a Triglyceride-Mimetic Prodrug

    Article • Pharmaceutical Research, December 2014, Springer Science + Business Media

    Christopher Porter

  63. An in Vitro Digestion Test That Reflects Rat Intestinal Conditions To Probe the Importance of Formulation Digestion vs First Pass Metabolism in Danazol Bioavailability from Lipid Based Formulations

    Article • Molecular Pharmaceutics, November 2014, American Chemical Society (ACS)

    Christopher Porter

  64. In vitro–in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623

    Article • European Journal of Pharmaceutics and Biopharmaceutics, November 2014, Elsevier

    Christopher Porter

  65. Nano-chemotherapeutics: Maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers

    Article • Journal of Controlled Release, November 2014, Elsevier

    Christopher Porter

  66. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations. 5. Lipolysis of Representative Formulations by Gastric Lipase

    Article • Pharmaceutical Research, October 2014, Springer Science + Business Media

    Christopher Porter

  67. ‘Stealth’ lipid-based formulations: Poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug

    Article • Journal of Controlled Release, October 2014, Elsevier

    Christopher Porter

  68. Characterization of Two Distinct Modes of Drug Binding to Human Intestinal Fatty Acid Binding Protein

    Article • ACS Chemical Biology, September 2014, American Chemical Society (ACS)

    Christopher Porter, Professor Martin J Scanlon

  69. Digestion of Phospholipids after Secretion of Bile into the Duodenum Changes the Phase Behavior of Bile Components

    Article • Molecular Pharmaceutics, August 2014, American Chemical Society (ACS)

    Christopher Porter

  70. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 4: Proposing a New Lipid Formulation Performance Classification System

    Article • Journal of Pharmaceutical Sciences, August 2014, Elsevier

    Christopher Porter

  71. Lipid-Based Formulations Solidified Via Adsorption onto the Mesoporous Carrier Neusilin® US2: Effect of Drug Type and Formulation Composition on In Vitro Pharmaceutical Performance

    Article • Journal of Pharmaceutical Sciences, June 2014, Elsevier

    Christopher Porter

  72. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy

    Article • Journal of Controlled Release, June 2014, Elsevier

    Christopher Porter

  73. The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol

    Article • Journal of Pharmacy and Pharmacology, May 2014, Wiley

    Christopher Porter

  74. Choice of Nonionic Surfactant Used to Formulate Type IIIA Self-Emulsifying Drug Delivery Systems and the Physicochemical Properties of the Drug Have a Pronounced Influence on the Degree of Drug Supersaturation that Develops During In Vitro Digestion

    Article • Journal of Pharmaceutical Sciences, April 2014, Elsevier

    Christopher Porter

  75. Targeted delivery of a model immunomodulator to the lymphatic system: Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies

    Article • Journal of Controlled Release, March 2014, Elsevier

    Christopher Porter

  76. Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration

    Article • Antimicrobial Agents and Chemotherapy, February 2014, ASM Journals

    Dr Kashyap Patel, Professor Roger L Nation, Christopher Porter

  77. The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats

    Article • Molecular Pharmaceutics, February 2014, American Chemical Society (ACS)

    Christopher Porter

  78. Non-linear Increases in Danazol Exposure with Dose in Older vs. Younger Beagle Dogs: The Potential Role of Differences in Bile Salt Concentration, Thermodynamic Activity, and Formulation Digestion

    Article • Pharmaceutical Research, January 2014, Springer Science + Business Media

    Christopher Porter

  79. Ionic liquids provide unique opportunities for oral drug delivery: structure optimization and in vivo evidence of utility

    Article • Chemical Communications, January 2014, Royal Society of Chemistry

    Christopher Porter

  80. Gastric Pre-Processing Is an Important Determinant of the Ability of Medium-Chain Lipid Solution Formulations to Enhance Oral Bioavailability in Rats

    Article • Journal of Pharmaceutical Sciences, November 2013, Elsevier

    Christopher Porter

  81. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin

    Article • Journal of Controlled Release, November 2013, Elsevier

    Christopher Porter

  82. Recent Advances in Lipid-Based Formulation Technology

    Article • Pharmaceutical Research, October 2013, Springer Science + Business Media

    Christopher Porter

  83. Population Pharmacokinetics of Colistin Methanesulfonate in Rats: Achieving Sustained Lung Concentrations of Colistin for Targeting Respiratory Infections

    Article • Antimicrobial Agents and Chemotherapy, August 2013, ASM Journals

    Dr Kashyap Patel, Christopher Porter

  84. Evaluation of the Structural Determinants of Polymeric Precipitation Inhibitors Using Solvent Shift Methods and Principle Component Analysis

    Article • Molecular Pharmaceutics, August 2013, American Chemical Society (ACS)

    Christopher Porter

  85. Pulmonary Administration of PEGylated Polylysine Dendrimers: Absorption from the Lung versus Retention within the Lung Is Highly Size-Dependent

    Article • Molecular Pharmaceutics, August 2013, American Chemical Society (ACS)

    Christopher Porter

  86. Lipid-Based Formulations and Drug Supersaturation: Harnessing the Unique Benefits of the Lipid Digestion/Absorption Pathway

    Article • Pharmaceutical Research, July 2013, Springer Science + Business Media

    Christopher Porter

  87. The Potential for Drug Supersaturation during Intestinal Processing of Lipid-Based Formulations May Be Enhanced for Basic Drugs

    Article • Molecular Pharmaceutics, July 2013, American Chemical Society (ACS)

    Christopher Porter

  88. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine

    Article • European Journal of Pharmaceutical Sciences, July 2013, Elsevier

    Christopher Porter

  89. The Impact of Lymphatic Transport on the Systemic Disposition of Lipophilic Drugs

    Article • Journal of Pharmaceutical Sciences, July 2013, Elsevier

    Christopher Porter

  90. Lipid Absorption Triggers Drug Supersaturation at the Intestinal Unstirred Water Layer and Promotes Drug Absorption from Mixed Micelles

    Article • Pharmaceutical Research, June 2013, Springer Science + Business Media

    Christopher Porter

  91. Computational Prediction of Drug Solubility in Lipid Based Formulation Excipients

    Article • Pharmaceutical Research, June 2013, Springer Science + Business Media

    Christopher Porter

  92. A Simple Quantitative Approach for the Determination of Long and Medium Chain Lipids in Bio-relevant Matrices by High Performance Liquid Chromatography with Refractive Index Detection

    Article • AAPS PharmSciTech, June 2013, American Association of Pharmaceutical Scientists (AAPS)

    Christopher Porter

  93. PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases

    Article • Journal of Controlled Release, June 2013, Elsevier

    Christopher Porter

  94. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations

    Article • Pharmaceutical Research, May 2013, Springer Science + Business Media

    Christopher Porter

  95. Intestinal Bile Secretion Promotes Drug Absorption from Lipid Colloidal Phases via Induction of Supersaturation

    Article • Molecular Pharmaceutics, May 2013, American Chemical Society (ACS)

    Christopher Porter

  96. Silica–lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation

    Article • Journal of Controlled Release, April 2013, Elsevier

    Christopher Porter

  97. A Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport

    Article • Pharmaceutical Research, February 2013, Springer Science + Business Media

    Christopher Porter

  98. The Effect of Administered Dose of Lipid-Based Formulations on the In Vitro and In Vivo Performance of Cinnarizine as a Model Poorly Water-Soluble Drug

    Article • Journal of Pharmaceutical Sciences, February 2013, Elsevier

    Christopher Porter

  99. In vitro digestion testing of lipid-based delivery systems: Calcium ions combine with fatty acids liberated from triglyceride rich lipid solutions to form soaps and reduce the solubilization capacity of colloidal digestion products

    Article • International Journal of Pharmaceutics, January 2013, Elsevier

    Christopher Porter

  100. Toward the Establishment of Standardizedin VitroTests for Lipid-Based Formulations. 2. The Effect of Bile Salt Concentration and Drug Loading on the Performance of Type I, II, IIIA, IIIB, and IV Formulations duringin VitroDigestion

    Article • Molecular Pharmaceutics, November 2012, American Chemical Society (ACS)

    Christopher Porter

  101. Incomplete Desorption of Liquid Excipients Reduces thein Vitroandin VivoPerformance of Self-Emulsifying Drug Delivery Systems Solidified by Adsorption onto an Inorganic Mesoporous Carrier

    Article • Molecular Pharmaceutics, September 2012, American Chemical Society (ACS)

    Christopher Porter

  102. Intravenous Dosing Conditions May Affect Systemic Clearance for Highly Lipophilic Drugs: Implications for Lymphatic Transport and Absolute Bioavailability Studies

    Article • Journal of Pharmaceutical Sciences, September 2012, Elsevier

    Christopher Porter

  103. Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 1: Method Parameterization and Comparison of In Vitro Digestion Profiles Across a Range of Representative Formulations

    Article • Journal of Pharmaceutical Sciences, September 2012, Elsevier

    Christopher Porter

  104. Lipid Digestion as a Trigger for Supersaturation: Evaluation of the Impact of Supersaturation Stabilization on the in Vitro and in Vivo Performance of Self-Emulsifying Drug Delivery Systems

    Article • Molecular Pharmaceutics, June 2012, American Chemical Society (ACS)

    Christopher Porter

  105. Association of Chemotherapeutic Drugs with Dendrimer Nanocarriers: An Assessment of the Merits of Covalent Conjugation Compared to Noncovalent Encapsulation

    Article • Molecular Pharmaceutics, March 2012, American Chemical Society (ACS)

    Christopher Porter

  106. Doxorubicin-Conjugated PEGylated Dendrimers Show Similar Tumoricidal Activity but Lower Systemic Toxicity When Compared to PEGylated Liposome and Solution Formulations in Mouse and Rat Tumor Models

    Article • Molecular Pharmaceutics, March 2012, American Chemical Society (ACS)

    Christopher Porter

  107. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems

    Article • Nanomedicine Nanotechnology Biology and Medicine, January 2012, Elsevier

    Christopher Porter

  108. Correction to “Targeted Drug Delivery to Lymphocytes: A Route to Site-Specific Immunomodulation?”

    Article • Molecular Pharmaceutics, December 2011, American Chemical Society (ACS)

    Christopher Porter

  109. Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration

    Article • Drug Delivery and Translational Research, November 2011, Springer Science + Business Media

    Christopher Porter

  110. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance

    Article • Journal of Pharmaceutical Sciences, November 2011, Elsevier

    Christopher Porter

  111. Targeting the lymphatics using dendritic polymers (dendrimers)

    Article • Advanced Drug Delivery Reviews, September 2011, Elsevier

    Christopher Porter

  112. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties

    Article • Nanomedicine, August 2011, Future Medicine

    Christopher Porter

  113. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration

    Article • Journal of Controlled Release, July 2011, Elsevier

    Christopher Porter

  114. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker

    Article • Journal of Controlled Release, June 2011, Elsevier

    Christopher Porter

  115. Fatty Acid Binding Proteins: Potential Chaperones of Cytosolic Drug Transport in the Enterocyte?

    Article • Pharmaceutical Research, April 2011, Springer Science + Business Media

    Christopher Porter, Professor Martin J Scanlon

  116. Capping Methotrexate α-Carboxyl Groups Enhances Systemic Exposure and Retains the Cytotoxicity of Drug Conjugated PEGylated Polylysine Dendrimers

    Article • Molecular Pharmaceutics, April 2011, American Chemical Society (ACS)

    Christopher Porter

  117. Preparation, crystallization and preliminary X-ray diffraction analysis of two intestinal fatty-acid binding proteins in the presence of 11-(dansylamino)undecanoic acid

    Article • Acta Crystallographica Section F Structural Biology and Crystallization Communications, January 2011, International Union of Crystallography

    Christopher Porter, Professor Martin J Scanlon

  118. Targeted Drug Delivery to Lymphocytes: A Route to Site-Specific Immunomodulation?

    Article • Molecular Pharmaceutics, December 2010, American Chemical Society (ACS)

    Christopher Porter

  119. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility

    Article • Journal of Drug Targeting, October 2010, Informa Healthcare

    Christopher Porter

  120. The Mechanism of Lymphatic Access of Two Cholesteryl Ester Transfer Protein Inhibitors (CP524,515 and CP532,623) and Evaluation of Their Impact on Lymph Lipoprotein Profiles

    Article • Pharmaceutical Research, July 2010, Springer Science + Business Media

    Christopher Porter

  121. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media

    Article • Journal of Pharmacy and Pharmacology, June 2010, Royal Pharmaceutical Society (Pharmaceutical Press)

    Christopher Porter

  122. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation

    Article • Journal of Pharmacy and Pharmacology, June 2010, Royal Pharmaceutical Society (Pharmaceutical Press)

    Christopher Porter

  123. The Role of the Intestinal Lymphatics in the Absorption of Two Highly Lipophilic Cholesterol Ester Transfer Protein Inhibitors (CP524,515 and CP532,623)

    Article • Pharmaceutical Research, March 2010, Springer Science + Business Media

    Christopher Porter

  124. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats

    Article • Journal of Controlled Release, December 2009, Elsevier

    Christopher Porter

  125. Partly-PEGylated Poly-L-lysine Dendrimers Have Reduced Plasma Stability and Circulation Times Compared With Fully PEGylated Dendrimers

    Article • Journal of Pharmaceutical Sciences, October 2009, Elsevier

    Christopher Porter

  126. Probing the Fibrate Binding Specificity of Rat Liver Fatty Acid Binding Protein

    Article • Journal of Medicinal Chemistry, September 2009, American Chemical Society (ACS)

    Christopher Porter, Professor Martin J Scanlon

  127. Lymphatic Transport of Methylnortestosterone Undecanoate (MU) and the Bioavailability of Methylnortestosterone Are Highly Sensitive to the Mass of Coadministered Lipid after Oral Administration of MU

    Article • Journal of Pharmacology and Experimental Therapeutics, August 2009, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  128. Pharmacokinetics and Tumor Disposition of PEGylated, Methotrexate Conjugated Poly-l-lysine Dendrimers

    Article • Molecular Pharmaceutics, August 2009, American Chemical Society (ACS)

    Christopher Porter

  129. Oral Bioavailability Assessment and Intestinal Lymphatic Transport of Org 45697 and Org 46035, Two Highly Lipophilic Novel Immunomodulator Analogues

    Article • Current Drug Delivery, August 2009, Bentham Science Publishers

    Christopher Porter

  130. Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism

    Article • Pharmaceutical Research, March 2009, Springer Science + Business Media

    Christopher Porter

  131. Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein

    Article • Molecular and Cellular Biochemistry, January 2009, Springer Science + Business Media

    Christopher Porter, Professor Martin J Scanlon

  132. An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity

    Article • Journal of Pharmacy and Pharmacology, October 2008, Wiley

    Christopher Porter

  133. Characterization of the Drug Binding Specificity of Rat Liver Fatty Acid Binding Protein

    Article • Journal of Medicinal Chemistry, July 2008, American Chemical Society (ACS)

    Christopher Porter, Professor Martin J Scanlon

  134. The Impact of Molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Polyl-Lysine Dendrimers

    Article • Molecular Pharmaceutics, June 2008, American Chemical Society (ACS)

    Christopher Porter

  135. Enhancing intestinal drug solubilisation using lipid-based delivery systems

    Article • Advanced Drug Delivery Reviews, March 2008, Elsevier

    Christopher Porter

  136. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies

    Article • Advanced Drug Delivery Reviews, March 2008, Elsevier

    Christopher Porter

  137. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update

    Article • Advanced Drug Delivery Reviews, March 2008, Elsevier

    Christopher Porter

  138. Lipid-based systems for the enhanced delivery of poorly water soluble drugs

    Article • Advanced Drug Delivery Reviews, March 2008, Elsevier

    Christopher Porter

  139. Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after Oral Administration of Lipidic Self-Emulsifying Formulations to Dogs

    Article • Journal of Pharmaceutical Sciences, February 2008, Elsevier

    Christopher Porter

  140. Use of plasma proteins as solubilizing agents in in vitro permeability experiments: Correction for unbound drug concentration using the reciprocal permeability approach

    Article • Journal of Pharmaceutical Sciences, January 2008, Elsevier

    Christopher Porter

  141. Impact of Surface Derivatization of Poly-l-lysine Dendrimers with Anionic Arylsulfonate or Succinate Groups on Intravenous Pharmacokinetics and Disposition

    Article • Molecular Pharmaceutics, December 2007, American Chemical Society (ACS)

    Christopher Porter

  142. Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model

    Article • Drug Metabolism and Disposition, September 2007, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  143. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats

    Article • International Journal of Pharmaceutics, August 2007, Elsevier

    Christopher Porter

  144. Low Dose Lipid Formulations: Effects on Gastric Emptying and Biliary Secretion

    Article • Pharmaceutical Research, July 2007, Springer Science + Business Media

    Christopher Porter

  145. Examination of the Role of Intestinal Fatty Acid-Binding Protein in Drug Absorption Using a Parallel Artificial Membrane Permeability Assay

    Article • Chemistry & Biology, April 2007, Elsevier

    Christopher Porter, Professor Martin J Scanlon

  146. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs

    Article • Nature Reviews Drug Discovery, March 2007, Nature

    Christopher Porter

  147. Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs

    Article • Pharmaceutical Research, February 2007, Springer Science + Business Media

    Christopher Porter

  148. Impact of Cremophor-EL and Polysorbate-80 on Digoxin Permeability across Rat Jejunum: Delineation of Thermodynamic and Transporter Related Events Using the Reciprocal Permeability Approach

    Article • Journal of Pharmaceutical Sciences, February 2007, Elsevier

    Christopher Porter

  149. Cationic Poly-l-lysine Dendrimers:  Pharmacokinetics, Biodistribution, and Evidence for Metabolism and Bioresorption after Intravenous Administration to Rats

    Article • Molecular Pharmaceutics, October 2006, American Chemical Society (ACS)

    Christopher Porter

  150. Permeability assessment of poorly water‐soluble compounds under solubilizing conditions: The reciprocal permeability approach

    Article • Journal of Pharmaceutical Sciences, October 2006, Elsevier

    Christopher Porter

  151. Lymphatic fatty acids in canines dosed with pharmaceutical formulations containing structured triacylglycerols

    Article • European Journal of Lipid Science and Technology, September 2006, Wiley

    Dr Rene Holm, Christopher Porter

  152. The Absorption of Darbepoetin Alfa Occurs Predominantly via the Lymphatics Following Subcutaneous Administration to Sheep

    Article • Pharmaceutical Research, August 2006, Springer Science + Business Media

    Christopher Porter

  153. An Acute and Coincident Increase in FABP Expression and Lymphatic Lipid and Drug Transport Occurs During Intestinal Infusion of Lipid-Based Drug Formulations to Rats

    Article • Pharmaceutical Research, July 2006, Springer Science + Business Media

    Christopher Porter

  154. Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone

    Article • Journal of Pharmacy and Pharmacology, June 2006, Wiley

    Christopher Porter

  155. AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT

    Article • Drug Metabolism and Disposition, February 2006, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  156. An improved method for the purification of rat liver-type fatty acid binding protein from Escherichia coli

    Article • Protein Expression and Purification, November 2005, Elsevier

    Christopher Porter, Professor Martin J Scanlon

  157. The Lymph Lipid Precursor Pool Is a Key Determinant of Intestinal Lymphatic Drug Transport

    Article • Journal of Pharmacology and Experimental Therapeutics, October 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  158. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire® core

    Article • Journal of Controlled Release, October 2005, Elsevier

    Christopher Porter

  159. Tissue uptake of DDT is independent of chylomicron metabolism

    Article • Archives of Toxicology, September 2005, Springer Science + Business Media

    Christopher Porter

  160. Bile Increases Intestinal Lymphatic Drug Transport in the Fasted Rat

    Article • Pharmaceutical Research, August 2005, Springer Science + Business Media

    Christopher Porter

  161. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water‐soluble drug

    Article • Journal of Pharmaceutical Sciences, March 2005, Elsevier

    Christopher Porter

  162. Subcutaneous drug delivery and the role of the lymphatics

    Article • Drug Discovery Today Technologies, March 2005, Elsevier

    Christopher Porter

  163. The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-binding Protein

    Article • Journal of Biological Chemistry, February 2005, American Society for Biochemistry & Molecular Biology (ASBMB)

    Christopher Porter, Professor Martin J Scanlon

  164. Lymphatic Absorption Is the Primary Contributor to the Systemic Availability of Epoetin Alfa following Subcutaneous Administration to Sheep

    Article • Journal of Pharmacology and Experimental Therapeutics, December 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  165. A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs

    Article • Journal of Controlled Release, September 2004, Elsevier

    Christopher Porter

  166. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine

    Article • Journal of Pharmaceutical Sciences, May 2004, Elsevier

    Christopher Porter

  167. Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins

    Article • Journal of Controlled Release, March 2004, Elsevier

    Christopher Porter

  168. Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep

    Article • Journal of Pharmacology and Experimental Therapeutics, February 2004, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  169. Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid‐based delivery systems: A phase diagram approach

    Article • Journal of Pharmaceutical Sciences, February 2004, Elsevier

    Christopher Porter

  170. Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations

    Article • Pharmaceutical Research, February 2004, Springer Science + Business Media

    Christopher Porter

  171. Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model

    Article • Journal of Pharmacy and Pharmacology, January 2004, Wiley

    Christopher Porter

  172. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides

    Article • European Journal of Pharmaceutical Sciences, September 2003, Elsevier

    Christopher Porter

  173. Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs

    Article • Journal of Pharmacology and Experimental Therapeutics, June 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  174. Using the Polymer Partitioning Method to Probe the Thermodynamic Activity of Poorly Water‐soluble Drugs Solubilized in Model Lipid Digestion Products

    Article • Journal of Pharmaceutical Sciences, June 2003, Elsevier

    Christopher Porter

  175. Separation and Characterization of the Colloidal Phases Produced on Digestion of Common Formulation Lipids and Assessment of Their Impact on the Apparent Solubility of Selected Poorly Water-Soluble Drugs

    Article • Journal of Pharmaceutical Sciences, March 2003, Elsevier

    Christopher Porter

  176. A Kinetic Evaluation of the Absorption, Efflux, and Metabolism of Verapamil in the Autoperfused Rat Jejunum

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2003, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Christopher Porter

  177. Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrineIn Vivo?

    Article • Biopharmaceutics & Drug Disposition, January 2003, Wiley

    Christopher Porter

  178. A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs

    Article • Journal of Pharmaceutical Sciences, March 2002, Elsevier

    Christopher Porter

  179. The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil

    Article • Journal of Pharmacy and Pharmacology, December 2001, Wiley

    Christopher Porter

  180. In vitro assessment of oral lipid based formulations

    Article • Advanced Drug Delivery Reviews, October 2001, Elsevier

    Christopher Porter

  181. Lipid-Based Formulations for Oral Administration

    Article • August 2001, Taylor & Francis

    Christopher Porter

  182. LIPID-BASED FORMULATIONS FOR ORAL ADMINISTRATION: OPPORTUNITIES FOR BIOAVAILABILITY ENHANCEMENT AND LIPOPROTEIN TARGETING OF LIPOPHILIC DRUGS

    Article • Journal of Receptors and Signal Transduction, January 2001, Taylor & Francis

    Christopher Porter

  183. Uptake of drugs into the intestinal lymphatics after oral administration

    Article • Advanced Drug Delivery Reviews, April 1997, Elsevier

    Christopher Porter

  184. Lipophilic prodrugs designed for intestinal lymphatic transport

    Article • Advanced Drug Delivery Reviews, May 1996, Elsevier

    Christopher Porter